Alkem Labs Q4 FY26 Earnings Call Transcript Released
Alkem Labs released its Q4 FY26 earnings call transcript on May 28, 2026. The company achieved a landmark FY26 with EBITDA crossing ₹3,000 crore. Q4 revenue was ₹3,603.3 crore (up 14.6% YoY), with international sales up 25.4%. Key growth drivers include the semaglutide launch and strong performance in India and the U.S. The Occlutech acquisition is nearing completion.
The announcement details significant financial performance for the quarter and full year, including key growth metrics and strategic developments like a major product launch and an acquisition. This information is highly material for investors and stakeholders.
The company reported strong financial results, exceeding EBITDA expectations and showcasing robust growth across its business segments. The successful launch of a key product and strategic initiatives like the Occlutech acquisition indicate a positive outlook.
Alkem Laboratories Limited has released the transcript of its Q4 FY2026 Earnings Conference Call, which was hosted on Thursday, May 28, 2026. The transcript is also available on the company's website.
The call featured insights from Managing Director Mr. Sandeep Singh, CEO Dr. Vikas Gupta, CFO Mr. Nitin Agrawal, and Head of Investor Relations Ms. Purvi Shah. Key discussions included the company's landmark FY26 performance, crossing INR3,000 crores in EBITDA, and strong growth across India and international markets. A significant highlight was the successful Day 1 launch of semaglutide in March 2026, achieving an 11% unit market share as per a recent IQVIA report.
Financially, for Q4 FY26, total revenue was INR36,033 million (approx. ₹3,603.3 crore) with a 14.6% YoY growth. India sales grew by 8.8% to INR23,245 million (approx. ₹2,324.5 crore), while international sales increased by 25.4% to INR12,223 million (approx. ₹1,222.3 crore). EBITDA for the quarter was INR5,174 million (approx. ₹517.4 crore), with an EBITDA margin of 14.4%. For the full year FY26, total revenue was INR1,47,123 million (approx. ₹14,712.3 crore), a 13.5% YoY growth. Full-year EBITDA stood at INR3,052 million (approx. ₹305.2 crore), with a margin of 20.4%.
The management discussed strategic priorities for FY27, focusing on strengthening execution, improving the portfolio mix, and expanding the differentiated pipeline. They acknowledged potential near-term headwinds from rising logistics and API costs due to the geopolitical environment but expressed confidence in mitigating these through proactive supply chain management and adequate inventory.
Discussions also covered the upcoming CEO transition, with a search for a new CEO underway. The Occlutech acquisition is expected to close in 45-60 days, with its full impact anticipated from Q2 onwards. The company also provided updates on its U.S. business, Enzene's performance, and the regulatory timeline for biosimilar launches.
What to do with a filing like this
Alkem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alkem Laboratories Limited. Read the original for the full detail.